US 12,433,906 B2
Pharmaceutical composition, methods for treating and uses thereof
Uli Christian Broedl, Mainz (DE); Sreeraj Macha, Basking Ridge, NJ (US); Maximilian von Eynatten, Erding (DE); and Hans-Juergen Woerle, Cully (CH)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Oct. 24, 2023, as Appl. No. 18/492,972.
Application 18/492,972 is a continuation of application No. 17/344,003, filed on Jun. 10, 2021, granted, now 11,833,166.
Application 17/344,003 is a continuation of application No. 16/288,192, filed on Feb. 28, 2019, granted, now 11,090,323, issued on Aug. 17, 2021.
Application 16/288,192 is a continuation of application No. 15/918,401, filed on Mar. 12, 2018, granted, now 10,258,637, issued on Apr. 16, 2019.
Application 15/918,401 is a continuation of application No. 14/918,727, filed on Oct. 21, 2015, granted, now 9,949,998, issued on Apr. 24, 2018.
Application 14/918,727 is a continuation of application No. 14/244,208, filed on Apr. 3, 2014, abandoned.
Claims priority of provisional application 61/908,991, filed on Nov. 26, 2013.
Claims priority of provisional application 61/808,804, filed on Apr. 5, 2013.
Prior Publication US 2024/0066046 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7034 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/7048 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/2018 (2013.01); A61K 9/2866 (2013.01); A61K 31/7034 (2013.01)] 41 Claims
 
1. A method of treating prediabetes, type 1 or type 2 diabetes mellitus in patient comprising administering empagliflozin to the patient, wherein the patient has moderate renal impairment or stage 3 chronic kidney disease (CKD).